Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia T… (NCT01407757) | Clinical Trial Compass
CompletedNot Applicable
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531
1,000 participantsStarted 2011-07
Plain-language summary
RATIONALE: DNA analysis of blood and tissue samples may help doctors predict how well patients will respond to treatment. It may also help doctors learn more about how gemtuzumab ozogamicin works in the body.
PURPOSE: This research study is looking at gemtuzumab ozogamicin in DNA samples from patients with acute myeloid leukemia treated on COG-AAML0531.
Who can participate
Age range
29 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosed with acute myeloid leukemia
* DNA samples from patients treated on COG-AAML0531
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was studying genetic changes in a protein called CD33 to see if they affect how well gemtuzumab ozogamicin works — does my child's leukemia show any CD33 genetic variations that might matter for their treatment?
2Since this study has already been completed, have any results been published, and if so, do those findings change how you would approach gemtuzumab ozogamicin as part of my child's treatment plan?
3The original treatment trial this is linked to, COG-AAML0531, used gemtuzumab ozogamicin in pediatric AML patients — based on what was learned from that study, is gemtuzumab ozogamicin still considered a standard or recommended option for my child's type of leukemia?
4Could my child's CD33 gene profile be tested as part of their current diagnostic workup, and would that information actually influence which treatment approach you recommend?
5If the research from this study suggests that certain CD33 genetic changes predict a poorer response to gemtuzumab ozogamicin, are there alternative treatment strategies we should be discussing instead?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Genetic changes in CD33 impact outcome of gemtuzumab ozogamicin-based therapy